Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

BEACON-IPF close out activities continuePreviously announced workforce and operational realignment largely completePhase 1 ...

Detailed price information for Cumberland Pharmaceu (CPIX-Q) from The Globe and Mail including charting and trades.

Kristy Smith says in June she was diagnosed with idiopathic pulmonary fibrosis which caused scarring on the lungs and makes ...

The 2025 World Bronchiectasis Conference highlighted new research on bronchiectasis and NTM - plus an emerging ...

In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

A new AI tool helps predict survival in fibrotic lung disease, outperforming traditional clinical and imaging methods in a study of over 1,200 patients.

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

Senolytic Supplements Market to Reach $350 Million by 2025, Poised for 15% CAGR Through 2032 Driven by growing focus on healthy aging and breakthroughs in cellular senescence-targeted therapies The ...